KLK3 and prostate cancer: Szmulewitz et al. randomly separated 15 prostate cancer patients (median PSA of 11.1 ng/ml, range from 5.2-63.6 ng/ml) who received androgen ablation plus anti-androgen therapy and withdrew without metastatic disease into three groups.